ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PROF / insiders
UTMD (62) OSUR (31) INFU (77) ANIK (53) ⌘ Pro Terminal β†’

Profound Medical Corp. (PROF) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.73 +2.44% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.75

Profound Medical Corp. (PROF) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $240.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PROF Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.73 (+2.44% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PROF compare to UTMD and OSUR in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PROF?
β–Ό

Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.75 (+0.25%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (40/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (7)Whales (10)SEC (14)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.2% Base Target
$9 Bull$6 Base$5 Bear
πŸ“¬ FREE PROF RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PROF)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
πŸ” WHY PROF SCORES 40/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)

Altman Z-Score 5.97 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Whale & Options Positioning+10/20 pts (25% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
48
Grade D$7.01-15.5% Next Q
Q2 (-2Q)
45
Grade D$5.92-4.7% Next Q
Q3 (-1Q)
43
Grade D$5.64+19.3% Next Q
Current
40
Grade D-$6.73-7.4% Hist 90D Ξ±
Trajectory: D (48) β†’ D- (40)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PROF Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PROF currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.20) and Max Pain ($7.07) forces dealer call-delta covering toward $9.40.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PROFβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPROF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

PROF Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PROF)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PROF. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PROF)

  • βœ“Walkthrough of PROF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PROF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.45%πŸ“ HORIZONTAL RANGE
2026-11-03O $5.86H $6.73L $5.86C $6.73VOL 475.5K
RES: $7.40SUP: $5.07SMA50: $6.20SMA200: $6.65
$8.71$7.83$6.94$6.06$5.18RES $7.40SUP $5.07$6.732026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PROF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PROF Butterfly Map β†’ + Track PROF β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +65.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PROF today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PROF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PROF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PROF)

Health Care Rank #463 of 1015 βš”οΈ UTMD vs PROF Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PROF vs. UTMD, OSUR, INFU, ANIK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Profound Medical Corp. (PROF) ranks #463 by composite RQD confidence (40/100, grade D-) and #550 by equity capitalization ($240.0M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with PROF at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PROF ACTIVE
Profound Medical Corp.
D- 40/100 β€” 70.8% -35.0% +2.44% $240.0M Benchmark Subject
UTMD
Utah Medical Products Inc.
C 62/100 β€” 57.1% 26.9% +3.64% $216.7M /utmd-vs-prof β†’
OSUR
OraSure Technologies Inc.
E 31/100 β€” 41.9% -35.0% -12.31% $271.7M /osur-vs-prof β†’
INFU
InfuSystems Holdings Inc.
B+ 77/100 43.4x 56.0% 12.8% -1.63% $280.2M /infu-vs-prof β†’
ANIK
Anika Therapeutics Inc.
D+ 53/100 β€” 56.6% -10.2% -7.35% $280.4M /anik-vs-prof β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001628808 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Profound Medical Corp. (PROF) reported GAAP revenue of $16.1M (+65.3% vs. FY2024 revenue of $9.7M , and +172.9% cumulative change since FY2023) , GAAP net income of -$42.6M, operating cash flow of -$38.2M, and free cash flow of -$38.4M (-63.7% YoY). On the balance sheet, PROF closed FY2025 with $77.5M in total assets against $4.5M in total debt (Altman Z-Score: 5.97, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.1M -$42.6M -$38.2M -$38.4M $77.5M $4.5M
FY2024 (FY) 2024-12-31 $9.7M -$27.8M -$23.5M -$23.5M $70.2M $2.9M
FY2023 (FY) 2023-12-31 $5.9M -$28.3M -$22.6M -$22.6M β€” β€”

3. PROF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PROF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Profound Medical Corp. (NASDAQ: PROF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $6.73 (+2.44% 1D, market cap $240.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PROF ranks #463 in composite RQD confidence.

How does PROF compare to UTMD and OSUR in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PROF carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 70.8%, and ROIC of -35.0%. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and OSUR (OraSure Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $271.7M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while UTMD leads on capital efficiency (26.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PROF?

Per PROF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628808), Profound Medical Corp. generated $16.1M in revenue (+65.3% YoY), -$42.6M in net income, and -$38.4M in free cash flow against $77.5M in total assets and $4.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PROF trading relative to its 50-day, 200-day, and 52-week technical levels?

PROF last traded at $6.73 (+2.44% on volume of 290,387 shares), positioning the stock +8.55% above its 50-day simple moving average ($6.20) and +1.20% above its 200-day simple moving average ($6.65). Across its 52-week range of $4.80 to $8.95, PROF sits at the 46.5% percentile with a 14-day RSI of 56.4 (BULLISH MOMENTUM) and an implied next-earnings move of Β±12.5% ($5.89 to $7.57).

Direct Sub-Reports: PROF RQD Cockpit PROF 12M Forecast PROF Earnings & Move PROF Dividends & DRIP PROF Insiders & 13F PROF Whale Options PROF Profit Sankey PROF News & Why
ROARABLE RATING BRIEF β€’ RQD 40/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

PROF β€” Profound Medical Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Profound Medical Corp. (PROF) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.73 (+2.44% 1D, market capitalization $240.0M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 70.8%, operating margin of -60.0%, and free cash flow yield of -17.93%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.97, Piotroski F-Score of 5/9, and Debt/Equity of 0.07x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Profound Medical Corp. (PROF) is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry. Gross margin is reported at 70.8%, per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Profound Medical Corp. (PROF) reported $16.1M in annual revenue (up from $9.7M in FY2024, +65.3% YoY) and -$42.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.9M revenue, -$28.3M net income) through FY2025, PROF scaled operating cash flow to -$38.2M and free cash flow to -$38.4M, backed by $77.5M in total assets against $4.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.93% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $4.80 – $8.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are β€” The only sector-level context is the Health Care sector and Medical/Dental Instruments industry classification from the profile. Investors should treat any ripple analysis beyond that classification as unsupported by the provided sources.

  • Key Question #1: Can PROF sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $16.1M and free cash flow of -$38.4M, how will capital allocation balance growth reinvestment against $4.5M in total debt?
  • Key Question #3: How sensitive is PROF's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PROF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Profound Medical Corp. (PROF) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PROF Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PROF Bull vs. Bear Conversation Board β€” What's Your Call at $6.73?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PROF 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PROF:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $8.02 (+22.1%)
πŸ“Œ Pinned Debate

Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash

Picked up a starter position in PROF in my $100K Virtual Cash book at $6.57. Revenue grew from $5.9M in FY 2023 to $16.1M in FY 2025 while the forensic balance sheet scored 14/20 with Debt/Equity of 0.07 and cash of $59.7M against debt of $4.5M.. Trading inside a $4.80–$8.95 52-week range with -17.93% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

SectorRotator πŸ‚ BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (70.8%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $5.39 (-18.0%)
Spot @ $6.57

Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction sco

Here is the bear case nobody on the bull side wants to address on PROF: Operating income fell to -$41.3M in FY 2025 with FCF of -$38.4M and FCF yield of -17.93%, while ROIC is -35% and insider conviction scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE